The information contained in company statements should be considered accurate only as of the date of the company statement. We disclaim any obligation to supplement or update the information in these company statements.

Corporate Statement Regarding Opzelura (ruxolitinib) Cream

November 2, 2021

Incyte Announces 2021 Incyte Ingenuity Award Program Recipients, Recognizing Innovative Solutions for the GVHD Community

October 29, 2021

Incyte Ranked Second Among Science Magazine’s 2021 Top Biopharma Employers

October 28, 2021

Incyte Named to Newsweek’s List of America’s Most Loved Workplaces for 2021

October 22, 2021

Incyte Announces Progress on Global Responsibility Initiatives and Sets Corporate Goals for the Next Four Years

July 28, 2021

Incyte Statement Regarding U.S. Department of Justice Settlement

May 4, 2021

Annual Call for Submissions Open for the Incyte Ingenuity Award Program

February 24, 2021

Incyte Joins the Myeloproliferative Neoplasm (MPN) Community in Recognizing MPN Awareness Day and the 10th Anniversary of Blood Cancer Awareness Month

September 1, 2020

Data from Investigator Initiated Study of Ruxolitinib in Patients with Severe COVID-19 Published in the Journal of Allergy and Clinical Immunology

May 26, 2020

Incyte Provides Statement on NIH Initiated Trial of Baricitinib in Combination with Remdesivir for Patients with COVID-19

May 8, 2020

Incyte Provides Updated Statement on Response to COVID-19

March 30, 2020

Incyte Named a Top Five Biopharma Employer by Science Magazine

October 24, 2019

Incyte Supports Wilmington Friends School Strategic Vision and Plan for the Future

October 10, 2019

Incyte Provides Statement on World Health Organization Global Medical Product Alert for Iclusig® (ponatinib)

Updated May 3, 2019

Incyte Provides Statement on Incyte Corporation versus Flexus Biosciences, Inc. Verdict

November 8, 2018